文献速递自身炎症与 IgG4 相关病

评估obexelimab治疗IgG4相关疾病患者的安全性、疗效及作用机制:一项开放标签、单臂、单中心、2期先导试验

Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial.
PubMed 文献 · Lancet Rheumatol · 2023-07-24

这项在麻省总医院开展的开放标签、单臂、单中心2期先导试验纳入15例活动性IgG4相关疾病患者,每2周静脉给予5 mg/kg obexelimab共24周;第169天12例(80%)达到主要终点,14例(93%)为应答者,13例(87%)报告不良事件,其中1例输注反应导致停药。

要点

  • 15例活动性IgG4相关疾病患者中,12例(80%)在第169天达到主要终点(IgG4-RD RI较基线下降≥2)。
  • 14例(93%)在任意访视达到IgG4-RD RI较基线下降≥2,被定义为应答者。
  • 13例(87%)报告不良事件,其中1例输注反应导致治疗中止。

核心结论

  • 除1例患者外,所有患者对obexelimab治疗均有临床应答。
  • obexelimab治疗期间循环B细胞减少且无凋亡证据,停药后B细胞快速反弹,提示obexelimab可能使B细胞滞留于淋巴器官或骨髓。
  • 这些结果支持继续开发obexelimab用于治疗IgG4相关疾病。

研究设计与样本

  • 在美国马萨诸塞州波士顿的麻省总医院开展开放标签、单臂、单中心2期先导试验。
  • 纳入年龄18-80岁、经IgG4相关疾病应答指数评分≥3分确认的活动性IgG4相关疾病患者。
  • 患者每2周静脉接受5 mg/kg obexelimab,共24周;基线使用糖皮质激素者预期入组后2个月内停用。
  • 主要终点为第169天IgG4相关疾病应答指数较基线下降≥2分的患者比例(即主要应答者)。
  • 在2016年2月24日至2016年12月21日期间入组15例患者。

主要发现

  • 15例患者中位年龄63岁(IQR 52-65),男性10例(67%)、女性5例(33%),白人12例(80%)。
  • 基线时15例中12例(80%)血清IgG4浓度中位升高至220 mg/dL(IQR 124-441),IgG4相关疾病应答指数评分中位12分(IQR 7-13)。
  • 15例中12例(80%)达到主要终点(主要应答者),14例(93%)被定义为应答者。
  • obexelimab治疗后观察到血清B细胞和浆母细胞较基线下降;但在有随访数据的多数患者中,末次obexelimab给药后42天内血清B细胞恢复至基线浓度的75%。
  • 15例中13例(87%)报告不良事件,其中1例(输注反应)导致治疗中止。

关键数值与推荐

  • 主要终点:第169天IgG4相关疾病应答指数较基线下降≥2分的患者比例,15例中12例(80%)达到。
  • 应答者定义:任意访视IgG4相关疾病应答指数较基线下降≥2分,15例中14例(93%)达到。
  • 给药方案:obexelimab 5 mg/kg静脉给药,每2周一次,共24周。
  • 不良事件按常见不良事件评价标准(CTCAE)4.3版1-5级(轻度、中度、重度、危及生命或死亡)分级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obexelimab is a bifunctional, non-cytolytic, humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. We aimed to evaluate the safety, clinical efficacy, and pharmacodynamic effects of obexelimab in patients with active IgG4-related disease. METHODS: We conducted an open-label, single-arm, single centre, phase 2 pilot trial at the Massachusetts General Hospital in Boston, MA, USA. Eligible patients were aged 18-80 years and had active IgG4-related disease confirmed by an IgG4-related disease responder index score of 3 or more. Patients received 5 mg/kg of obexelimab intravenously every 2 weeks for 24 weeks. Patients on glucocorticoids at baseline were expected to discontinue usage within 2 months following enrolment. The primary endpoint was the proportion of patients with a decrease of 2 or more from baseline in the IgG4-related disease responder index at day 169 (ie, primary responders). Patients who achieved a decrease of 2 or more at any visit were designated as responders. Adverse events were graded on a scale of 1-5 (ie, mild, moderate, severe, life-threatening, or death) according to the Common Terminology Criteria for Adverse Events grading scale (version 4.3). Exploratory analyses were quantification of B-cell CD19 receptor occupancy, plasmablast, total B-cell and CD4+ cytotoxic T-cell count by flow cytometry, and immunoglobulin concentrations by nephelometry. This study is registered with ClinicalTrials.gov, NCT02725476. FINDINGS: Between Feb 24, 2016, and Dec 21, 2016, we enrolled 15 patients. The median age was 63 years (IQR 52-65). Ten (67%) of 15 patients were male, five (33%) were female, and 12 (80%) were White. At baseline, 12 (80%) of 15 patients had an elevated median serum IgG4 concentration of 220 mg/dL (IQR 124-441), and the median IgG4-related disease responder index score was 12 (IQR 7-13). 12 (80%) of 15 patients achieved the primary endpoint (ie, primary responders), 14 (93%) were defined as responders. Reductions from baseline in serum B cells and plasmablasts were observed following treatment with obexelimab. However, in most patients with follow-up data, serum B cells recovered to 75% of baseline concentrations within 42 days of the final obexelimab dose. 13 (87%) of 15 patients reported adverse events, one of which (an infusion reaction) resulted in treatment discontinuation. INTERPRETATION: All patients except for one had clinical responses to obexelimab treatment. Both reductions in circulating B cells without evidence of apoptosis during obexelimab treatment and their rapid rebound after treatment discontinuation suggest that obexelimab might lead to B-cell sequestration in lymphoid organs or the bone marrow. These results support the continued development of obexelimab for the treatment of IgG4-related disease. FUNDING: Xencor, Zenas BioPharma, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and National Institute of Allergy and Infectious Diseases.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Perugino CA, Wallace ZS, Zack DJ, et al. Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial. Lancet Rheumatol. 2023. PMID: 38251576. doi:10.1016/S2665-9913(23)00157-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。